Novartis Buys Fougera for $1.5B, gets Generic Metrogel

Written by on May 3, 2012 in in the news, Metrogel 1% with 0 Comments


News today that the giant pharmaceutical company Novartis International is buying Fougera Pharmaceuticals.

Fougera is known to rosacea sufferers through the availability of generic metronidazole 0.75%. Fougera will brings its specialty in generics to Sandoz, the generics division of Novartis.

Who is Novartis?

Novartis was previously the manufacturer of Elidel (Pimecrolimus cream 1%).

Novartis are also trialling BFH772 for the redness of rosacea (NCT01449591). BFH772 is also being trialled for Psoriasis (NCT00987870).

BFH772 appears to be a metrondizaole variant of some sort, perhaps a genuine competitor to Metrogel 1%.

Hopefully this further signals Novartis as a company willing to invest in treatments for rosacea.

Press Release

Novartis to Buy Fougera Pharmaceuticals for $1.5 Billion


Novartis International agreed on Wednesday to buy Fougera Pharmaceuticals, a maker of generic skin care medicine, for $1.525 billion in cash. The move would make the company the biggest manufacturer in the field.

It is the latest round of consolidation in the health care industry, a sector that has had a number of deals over recent weeks.

Under the terms of the deal, Fougera will be folded into Sandoz, the generics division of Novartis. The acquisition would give Novartis a leading position in generic treatments for ailments like acne, eczema and rosacea. The combined business will have an estimated $620 million in annual global sales, mostly in the United States.

Related Articles

Read more about: in the news, Metrogel 1%

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed Connect on Pinterest Connect on Google Plus

Leave your comment here


Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.